Study of the Acceptability and Psychosocial Impact of Using a Telepresence Robot in the Living Space of Inpatients (ROBOLINK-e)

This study focuses on the mobile robot assist device for tele-interaction: the "COVEALINK 2" robot. This telepresence robot is designed for remote use inside the home. It works with an Internet connection (Wifi or 4G). It consists of a control interface (an application installed on the smartphone or tablet of the hospitalized patient) and a mobile robot placed in the home of the hospitalized patient (composed of a mobile platform, a visualization screen whose tilt is adjustable remotely for better adaptation to the interlocutors and an audio communication system). From the app installed on his smartphone or tablet, the patient hospitalized in the center for a long time (2 months minimum) will be able to start remotely (from the center where he is hospitalized) the robot and have it move within his home to communicate with the people present at the time of use (family, friends, neighbors etc.).

Study Overview

• Status: Completed
• Conditions: Motor Disorders; Cognitive Disability
• Intervention / Treatment: Device: Telepresence robot

• Study Type: Interventional
• Enrollment (Actual): 49
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Alsace
    • Mulhouse, Alsace, France, 68100
      • CR Mulhouse
    • Strasbourg, Alsace, France, 67000
      • IUR Clémenceau
  • Brittany Region
    • Ploemeur, Brittany Region, France, 56270
      • CMRRF de Kerpape
  • Pays de la Loire Region
    • Saint-Nazaire, Pays de la Loire Region, France, 44600
      • CMPR Côte d'Amour

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age ≧ 18 years old
• Affiliation to a social security scheme or beneficiary of such a scheme
• Having signed a free informed consent in writing
• Hospitalized in PRM for a foreseeable period of at least 60 days
• Living space compatible with the movement of the robot (verified by a home visit by the center's occupational therapist) and equipped with wifi
• Cognitive and motor functions compatible with the use of the tablet or phone independently, with learning capabilities to use the robot and the completion of questionnaires and interviews remotely
• Medically stable

Exclusion Criteria:

• Subject being in a period of exclusion from another protocol
• Mood and behavior disorders not stabilized
• Insufficient command of the French language
• Protected adults (guardianship / curatorship)
• Pregnant or breastfeeding women
• Persons deprived of their liberty
• Being unable to issue their consent
• Person who has already presented a form of addiction to technologies and / or video games

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Installation of a telepresence robot in the home of a disabled person hospitalized in a PRM center; From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,…)

Device: Telepresence robot; From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,…)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the medium-term acceptance of robotic tele-interaction	Measured with hospitalized patients using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication)	At 2 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the a priori acceptability of robotic tele-interaction	Measured with hospitalized patients using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication). Measure of the a priori acceptability on Day 0. A priori acceptability corresponds to the study of representations of the user upstream of any use of the technology.	Day 0
Evaluation of the short-term acceptance of robotic tele-interaction	Measured with hospitalized patients using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication). Measurement of acceptance at Day 30. The acceptance phase studies the user's judgment and impressions after the user's first interactions with the system	At 1 month
Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.	This assessment is done using validated measurement scale relating to depression and anxiety: HAD scale (Hospital Anxiety and Depression). The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items graded from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus making it possible to obtain two scores (maximum score for each score = 21 ).To screen for anxiety and depressive symptoms, the following interpretation is used for each of the scores (A and D): - 7 or less: no symptoms - 8 to 10: doubtful symptomatology - 11 and over: definite symptomatology.	Day 0
Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.	This assessment is done using validated measurement scale relating to psychological well-being: EBEP (Psychological Well-Being Scale). The Ryff scale of psychological well-being "is constructed from six key dimensions: autonomy, mastery of the environment, personal development, positive relationships, giving meaning to one's life and acceptance of life. self. It consists of 18 items sides 1 to 6, where 6 indicating strongly agree. A high total score indicates psychological well-being.	Day 0
Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.	This assessment is done using validated measurement scale relating to quality of life: questionnaire general SF-36 (Short Form 36 Healt Survey). The SF-36 questionnaire is a multidimensional questionnaire that assesses quality of life in relation to health status, regardless of causal pathology, gender, age and treatment. It assesses functioning and overall well-being using a questionnaire using 36 questions divided into 8 dimensions (physical functioning, role limitations related to physical health, physical pain, general health, vitality, functioning or social well-being, role limitations related to mental health, mental health).	Day 0
Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.	This assessment is done using validated measurement scale relating to level of social participation: LHS scale (London Handicap Scale). This scale questions everyday life by assessing mobility, physical independence, occupation (work, hobbies, vacations, etc.), social integration, perception of the outside world and economic independence. It takes the form of a questionnaire comprising 6 items rated from 0 to 1: - 1 = no handicap - 0 = maximum handicap.	Day 0
Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.	This assessment is done using validated measurement scale relating to depression and anxiety: HAD scale (Hospital Anxiety and Depression). The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items graded from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus making it possible to obtain two scores (maximum score for each score = 21 ).To screen for anxiety and depressive symptoms, the following interpretation is used for each of the scores (A and D): - 7 or less: no symptoms - 8 to 10: doubtful symptomatology - 11 and over: definite symptomatology.	At 2 months
Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.	This assessment is done using validated measurement scale relating to psychological well-being: EBEP (Psychological Well-Being Scale). The Ryff scale of psychological well-being "is constructed from six key dimensions: autonomy, mastery of the environment, personal development, positive relationships, giving meaning to one's life and acceptance of life. self. It consists of 18 items sides 1 to 6, where 6 indicating strongly agree. A high total score indicates psychological well-being.	At 2 months
Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.	This assessment is done using validated measurement scale relating to quality of life: questionnaire general SF-36 (Short Form 36 Healt Survey). The SF-36 questionnaire is a multidimensional questionnaire that assesses quality of life in relation to health status, regardless of causal pathology, gender, age and treatment. It assesses functioning and overall well-being using a questionnaire using 36 questions divided into 8 dimensions (physical functioning, role limitations related to physical health, physical pain, general health, vitality, functioning or social well-being, role limitations related to mental health, mental health).	At 2 months
Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.	This assessment is done using validated measurement scale relating to level of social participation: LHS scale (London Handicap Scale). This scale questions everyday life by assessing mobility, physical independence, occupation (work, hobbies, vacations, etc.), social integration, perception of the outside world and economic independence. It takes the form of a questionnaire comprising 6 items rated from 0 to 1: - 1 = no handicap - 0 = maximum handicap.	At 2 months
Evaluation of the a priori acceptability of robotic tele-interaction for users, relatives and members of the multidisciplinary team	Measurement with categories of users around the patient and members of the multidisciplinary team, using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication). Measurement of a priori acceptability on Day 0. A priori acceptability corresponds to the study of representations of the user upstream of any use of the technology.	Day 0
Evaluation of the medium-term acceptance of robotic tele-interaction for users, relatives and members of the multidisciplinary team	Measurement with categories of users around the patient and members of the multidisciplinary team, using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication). Measurement of acceptance at Day 60. The acceptance phase studies the user's judgment and impressions after the user's first interactions with the system.	At 2 months

Collaborators and Investigators

• Sponsor: Association APPROCHE
• Collaborators: LP3C, University of Rennes 2; COVEA
• Investigators: Principal Investigator: Thibaud Honoré, Doctor, CMRRF de Kerpape

Study record dates

Study Major Dates

• Study Start (Actual): October 24, 2020
• Primary Completion (Actual): January 18, 2024
• Study Completion (Actual): April 18, 2024

Study Registration Dates

• First Submitted: May 10, 2021
• First Submitted That Met QC Criteria: May 19, 2021
• First Posted (Actual): May 25, 2021

Study Record Updates

• Last Update Posted (Actual): March 6, 2026
• Last Update Submitted That Met QC Criteria: March 5, 2026
• Last Verified: February 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Motor Disorders
• Other Study ID Numbers: 2019-A02088-49

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No